These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 34625658)

  • 21. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells.
    Latancia MT; Leandro GDS; Bastos AU; Moreno NC; Ariwoola AA; Martins DJ; Ashton NW; Ribeiro VC; Hoch NC; Rocha CRR; Woodgate R; Menck CFM
    DNA Repair (Amst); 2024 Sep; 141():103715. PubMed ID: 39029375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
    J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
    Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
    Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.
    Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X
    Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression.
    Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM
    J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT.
    Duan C; He B; Wang Y; Liu W; Bao W; Yu L; Xin J; Gui H; Lei J; Yang Z; Liu J; Tao W; Qin J; Luo J; Dong Z
    Sci Rep; 2024 Aug; 14(1):20199. PubMed ID: 39215105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O
    Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M
    J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.